TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17426000

Group type: EXPERIMENTAL
Intervention: Cephalothin V (2.0 g) intravenous 30 min before the operation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ozone injection (6-10 ml ozone at 40 microg/ml) into the discs and 10 ml ozone into the paravertebral space
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 72
Study: 15668261

Group type: EXPERIMENTAL
Intervention: Axillary radiotherapy (RT)
Number of subjects: 435

Group type: COMPARATOR
Intervention: No axillary treatment
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 435
Study: 12195173

Group type: EXPERIMENTAL
Intervention: Experimental device (hearing aids)
Number of subjects: 720
Study: 10071005

Group type: EXPERIMENTAL
Intervention: Meta-analysis of individual trials with deliberately introduced heterogeneity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combining observational data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0
Study: 7879930

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine low dose (targeting plasma concentration of 0.15 ng/ml)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine medium dose (targeting plasma concentration of 0.30 ng/ml)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine high dose (targeting plasma concentration of 0.45 ng/ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2071729

Group type: EXPERIMENTAL
Intervention: Experimental self‐quitting guide emphasizing nicotine fading and other nonaversive behavioral strategies
Number of subjects: 2021

Group type: EXPERIMENTAL
Intervention: Self‐quitting guide with a support guide for the quitter's family and friends
Number of subjects: 2021

Group type: EXPERIMENTAL
Intervention: Self‐quitting and support guides along with four brief counselor calls
Number of subjects: 2021

Group type: COMPARATOR
Intervention: Control guide providing motivational and quit tips and referral to locally available guides and programs
Number of subjects: 2021
Study: 6666612

Group type: EXPERIMENTAL
Intervention: Hydromassage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 31958177

Group type: EXPERIMENTAL
Intervention: Worked examples highlighting salient features
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Worked examples highlighting discriminatory features
Number of subjects: 65

Group type: COMPARATOR
Intervention: Historical controls (medical students interpreting ECG rhythms without worked examples)
Number of subjects: 65
Study: 30711062

Group type: EXPERIMENTAL
Intervention: Incentive group (n = 948) received $30 per call for up to five calls and $40 for biochemically verified abstinence at 6 months.
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Control group (n = 952) did not receive financial incentives.
Number of subjects: 1900
Study: 29716077

Group type: EXPERIMENTAL
Intervention: Semi-quantum noise randomized cipher based on amplified spontaneous emission (ASE) light source employing Y-00 protocol
Number of subjects: 0
Study: 26814038

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 3 mcg · kg(‐1) plus oral placebo (Group IN DEX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral chloral hydrate 50 mg · kg(‐1) plus intranasal saline placebo (Group CH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral chloral hydrate
Number of subjects: 0
Study: 26922170

Group type: EXPERIMENTAL
Intervention: Pemetrexed and bevacizumab maintenance therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Pemetrexed maintenance therapy
Number of subjects: 110
Study: 23887135

Group type: EXPERIMENTAL
Intervention: Non-narrative blogs with health-related similarities
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Narrative blogs
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Non-narrative blogs
Number of subjects: 150
Study: 21289261

Group type: EXPERIMENTAL
Intervention: 300 mg of progesterone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 19204582

Group type: EXPERIMENTAL
Intervention: HJ‐151 pedometer
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: HJ‐720ITC pedometer
Number of subjects: 47

Group type: COMPARATOR
Intervention: HJ‐720ITC at the backpack position
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: HJ‐151 and HJ‐720ITC pedometers
Number of subjects: 47
Study: 16707870

Group type: EXPERIMENTAL
Intervention: Chewing gum (salivary stimulation) for 30 min after immersion in cola drink
Number of subjects: 9

Group type: COMPARATOR
Intervention: No treatment (erosion only)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Brushing immediately after immersion (0 min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Brushing after 60 min
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fluoride dentifrice brushing
Number of subjects: 9

Group type: COMPARATOR
Intervention: Erosion only
Number of subjects: 9
Study: 15013894

Group type: EXPERIMENTAL
Intervention: Daily patching (> or =2 hours a day) combined with at least 1 hour of near activities
Number of subjects: 66
Study: 11709795

Group type: EXPERIMENTAL
Intervention: Oral washes using a PCR detection system based on Pneumocystis major surface glycoprotein primers
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Oral washes using a PCR detection system based on mitochondrial large subunit rRNA primers
Number of subjects: 175

Group type: COMPARATOR
Intervention: Induced sputum positive for Pneumocystis
Number of subjects: 175

Group type: COMPARATOR
Intervention: Bronchoalveolar lavage (BAL) samples
Number of subjects: 175
Study: 9041342

Group type: EXPERIMENTAL
Intervention: 40‐microg S subunit vaccine
Number of subjects: 46

Group type: COMPARATOR
Intervention: 10‐microg S subunit vaccine
Number of subjects: 46

Group type: COMPARATOR
Intervention: mixed particle vaccine (pre‐S1, pre‐S2, and S subunit particles)
Number of subjects: 46
Study: 7613114

Group type: EXPERIMENTAL
Intervention: 400 ppb NO2
Number of subjects: 16

Group type: COMPARATOR
Intervention: Air
Number of subjects: 16
Study: 2152972

Group type: EXPERIMENTAL
Intervention: ACTH(4-9) analogue, Org 2766 (high dose: 1 mg/m²)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ACTH(4-9) analogue, Org 2766 (low dose: 0.25 mg/m²)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 497303

Group type: EXPERIMENTAL
Intervention: Pyridoxine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30503602

Group type: EXPERIMENTAL
Intervention: RAPP contact group
Number of subjects: 494

Group type: COMPARATOR
Intervention: Non-RAPP contact group
Number of subjects: 494
Study: 28476154

Group type: EXPERIMENTAL
Intervention: Adolescent Girls Empowerment Programme (AGEP)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Health voucher and bank account (additional components of AGEP)
Number of subjects: 10000
Study: 25136884

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Endeavor zotarolimus-eluting stents (ZES)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Resolute zotarolimus-eluting stents (ZES)
Number of subjects: 207
Study: 23278328

Group type: EXPERIMENTAL
Intervention: Automated bolus group
Number of subjects: 102

Group type: COMPARATOR
Intervention: Infusion group
Number of subjects: 102
Study: 21291333

Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 572

Group type: COMPARATOR
Intervention: Insulin lispro
Number of subjects: 572
Study: 19881458

Group type: EXPERIMENTAL
Intervention: Paravertebral block
Number of subjects: 24

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 24
Study: 16740528

Group type: EXPERIMENTAL
Intervention: Alternating pressure mattresses
Number of subjects: 1971

Group type: COMPARATOR
Intervention: Alternating pressure overlays
Number of subjects: 1971
Study: 15577788

Group type: EXPERIMENTAL
Intervention: Envoy System (totally implantable middle ear device)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Envoy System
Number of subjects: 7
Study: 11805557

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 60
Study: 9218237

Group type: EXPERIMENTAL
Intervention: Autogenic relaxation training facilitated through biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not receiving autogenic relaxation training)
Number of subjects: 0
Study: 7510078

Group type: EXPERIMENTAL
Intervention: FK‐506 intelligent dosing system (IDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RCCCT design guided by IDS
Number of subjects: 0
Study: 2133624

Group type: EXPERIMENTAL
Intervention: 1.5 g Mg pidolate (MAG2) three times a day for one month
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 18071

Group type: EXPERIMENTAL
Intervention: IM lorazepam
Number of subjects: 40

Group type: COMPARATOR
Intervention: IM pentobarbital
Number of subjects: 40
Study: 30311367

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5 mg per day)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 71
Study: 28588304

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Ketogenic (VLCK) diet
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Low-Calorie (LC) diet
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 181

Group type: COMPARATOR
Intervention: Energy-restriction treatments (VLCK and LC diets)
Number of subjects: 181
Study: 25156879

Group type: EXPERIMENTAL
Intervention: 400 μg of salbutamol
Number of subjects: 21
Study: 23172751

Group type: EXPERIMENTAL
Intervention: Lupuzor (200 μg) subcutaneously every 4 weeks
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Lupuzor (200 μg) subcutaneously every 2 weeks
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 21804623

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19309420

Group type: EXPERIMENTAL
Intervention: Home-based intervention training parents to work with children through modelling and coaching by teachers during weekly home visits
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study: 16397402

Group type: EXPERIMENTAL
Intervention: 5‐HT2A -1438 A/G polymorphism
Number of subjects: 132

Group type: COMPARATOR
Intervention: 5‐HTTLPR
Number of subjects: 132
Study: 15622574

Group type: EXPERIMENTAL
Intervention: Procedure for prolapse and hemorrhoids
Number of subjects: 156

Group type: COMPARATOR
Intervention: Ferguson hemorrhoidectomy
Number of subjects: 156
Study: 11694205

Group type: EXPERIMENTAL
Intervention: Group cessation intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 9220527

Group type: EXPERIMENTAL
Intervention: 200 micrograms salbutamol delivered from an MDI with a valved spacer (Aerochamber)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 600 micrograms salbutamol delivered via jet nebulizer (PariBaby)
Number of subjects: 13
Study: 8237402

Group type: EXPERIMENTAL
Intervention: Lomefloxacin tablet (400 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lomefloxacin capsule (400 mg)
Number of subjects: 10
Study: 3524844

Group type: EXPERIMENTAL
Intervention: Rociverine 20 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flavoxate 200 mg
Number of subjects: 40
Study: 29701091

Group type: EXPERIMENTAL
Intervention: Intramedullary nail fixation
Number of subjects: 321

Group type: COMPARATOR
Intervention: Locking plate fixation
Number of subjects: 321
Study: 27604774

Group type: EXPERIMENTAL
Intervention: Lower-protein infant formula (LPF)
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Lower-protein infant formula with additional active ingredients (LPFA)
Number of subjects: 1882

Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 1882
Study: 23034126

Group type: EXPERIMENTAL
Intervention: Nasal irrigation with normal saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-irrigation group
Number of subjects: 60
Study: 23796998

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg for 19 doses over 5 years)
Number of subjects: 3360

Group type: COMPARATOR
Intervention: Control (standard adjuvant systemic therapy alone)
Number of subjects: 3360
Study: 20842110

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 or 40 mg daily for 4 weeks
Number of subjects: 808

Group type: COMPARATOR
Intervention: Control group (continued current therapy)
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 808
Study: 18613278

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 14237

Group type: COMPARATOR
Intervention: Control (placebo or active diabetes medications)
Number of subjects: 14237

Group type: EXPERIMENTAL
Intervention: Rosiglitazone monotherapy versus placebo
Number of subjects: 14237

Group type: EXPERIMENTAL
Intervention: Rosiglitazone monotherapy versus sulfonylurea/metformin monotherapy
Number of subjects: 14237

Group type: EXPERIMENTAL
Intervention: Sulfonylurea + rosiglitazone versus sulfonylurea monotherapy
Number of subjects: 14237

Group type: EXPERIMENTAL
Intervention: Metformin + rosiglitazone versus metformin monotherapy
Number of subjects: 14237

Group type: EXPERIMENTAL
Intervention: Metformin + rosiglitazone versus metformin + sulfonylurea
Number of subjects: 14237

Group type: EXPERIMENTAL
Intervention: Sulfonylurea + metformin + rosiglitazone versus sulfonylurea + metformin
Number of subjects: 14237

Group type: EXPERIMENTAL
Intervention: Insulin + rosiglitazone versus insulin monotherapy
Number of subjects: 14237
Study: 15705433

Group type: EXPERIMENTAL
Intervention: IPS Empress inlays and onlays
Number of subjects: 34
Study: 12849762

Group type: EXPERIMENTAL
Intervention: L-dopa therapy (ON condition)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: No treatment (OFF condition)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (age-matched healthy subjects)
Number of subjects: 18
Study: 10383543

Group type: EXPERIMENTAL
Intervention: Propofol 6% SAZN
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol 1% SAZN
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diprivan-10
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 24
Study: 9060777

Group type: EXPERIMENTAL
Intervention: Caring/Old
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Caring/New
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Clinical care/Old
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Clinical care/New
Number of subjects: 135
Study: 1702795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 6685863

Group type: EXPERIMENTAL
Intervention: Receiving informed consent (after giving consent)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Receiving standard disclosure (before receiving consent)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Consent obtained just prior to discharge
Number of subjects: 628
Study: 30455075

Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 29920978

Group type: EXPERIMENTAL
Intervention: Vortioxetine (5 to 20 mg once daily)
Number of subjects: 0
Study: 26885925

Group type: EXPERIMENTAL
Intervention: HMF group (n=62)
Number of subjects: 122
Study: 24490977

Group type: EXPERIMENTAL
Intervention: Guided Self-Determination (GSD) intervention
Number of subjects: 120
Study: 22324948

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 10 mg weekly
Number of subjects: 41

Group type: COMPARATOR
Intervention: Chloroquine (CQ) 150 mg daily
Number of subjects: 41
Study: 19586140

Group type: EXPERIMENTAL
Intervention: Alcohol (0.65 g/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 17335316

Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination trials (antidepressant and antipsychotic)
Number of subjects: 100
Study: 15064262

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 micro g*kg(‐1) iv followed by 0.5 micro g*kg(‐1)*hr(‐1) infusion with morphine PCA (2 mg bolus, five minutes lockout, 2 mg*hr(‐1) infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tramadol 1.5 mg*kg(‐1) pre‐mixed with midazolam 30 micro g*kg(‐1) iv followed by tramadol PCA (20 mg bolus, five minute lockout, 20 mg*hr(‐1) infusion)
Number of subjects: 60
Study: 12126906

Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine (Group A: 50,000 PFU, Group B: 16,000 PFU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: VARILRIX (Group C: 40,000 PFU)
Number of subjects: 100
Study: 9614452

Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis during pregnancy
Number of subjects: 0
Study: 7861197

Group type: EXPERIMENTAL
Intervention: Brodimoprim 200mg tablet once daily for 8 to 12 days (including a loading dose of 2 tablets on the first day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Doxycycline 100mg tablet once daily for 8 to 12 days (including a loading dose of 2 tablets on the first day)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Brodimoprim
Number of subjects: 56

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 56
Study: 2782122

Group type: EXPERIMENTAL
Intervention: Exposure to palatable food stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no food during exposure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonpreferred food presented during exposure phase
Number of subjects: 0
Study: 58563

Group type: EXPERIMENTAL
Intervention: 6 per cent Dextran 60
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 per cent hydroxyethyl starch (HES)
Number of subjects: 0
Study: 31137125

Group type: EXPERIMENTAL
Intervention: Short-time training including face-to-face lectures and hand-by-hand operation training course
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Short-time training
Number of subjects: 28
Study: 28318515

Group type: EXPERIMENTAL
Intervention: Statin administration 24 hours or less preoperatively
Number of subjects: 3025

Group type: COMPARATOR
Intervention: Statin administration 24 to 72 hours preoperatively
Number of subjects: 3025

Group type: COMPARATOR
Intervention: Statin administration more than 72 hours or no dose
Number of subjects: 3025

Group type: COMPARATOR
Intervention: Statin dose of 20 mg or less
Number of subjects: 3025

Group type: EXPERIMENTAL
Intervention: Statin dose of more than 20 mg
Number of subjects: 3025

Group type: COMPARATOR
Intervention: No preoperative statin
Number of subjects: 3025
Study: 25061037

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Biofeedback Posture Trainer (Backtone)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Postural Education (Control)
Number of subjects: 96
Study: 23731498

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing for CYP450 2D6 and 2C19
Number of subjects: 207

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 207
Study: 21567258

Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: TVT-Secur
Number of subjects: 102
Study: 18577154

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16901644

Group type: EXPERIMENTAL
Intervention: Bromocriptine (D2 receptor agonist)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14604600

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11709645

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) with standard cycle (30 seconds)
Number of subjects: 95
Study: 9387945

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7639374

Group type: EXPERIMENTAL
Intervention: Interpleural infusion of 2% lidocaine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3281916

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31228006

Group type: EXPERIMENTAL
Intervention: Propofol (2.0, 1.5, and 1.2 mg/kg for young, middle, and elderly groups respectively)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopental (5.0, 4.0, and 3.0 mg/kg for young, middle, and elderly groups respectively)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study: 28877109

Group type: EXPERIMENTAL
Intervention: Viscoelastic foam overlay (VEFO) on top of the standard hospital mattress
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard hospital mattress with/without air overlay
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Viscoelastic foam overlay (VEFO)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard hospital mattress
Number of subjects: 110
Study: 25158925

Group type: EXPERIMENTAL
Intervention: Lubiprostone (48 μg/day) for 4 weeks
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 μg twice daily) for 48 weeks
Number of subjects: 124
Study: 24096771

Group type: EXPERIMENTAL
Intervention: Inhibition of miR‐487b
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upregulation of miR‐487b
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin II infusion
Number of subjects: 0
Study: 21461761

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (6 mg/kg)
Number of subjects: 8
Study: 18047576

Group type: EXPERIMENTAL
Intervention: N(2)O/O(2) plus local anaesthetic (LA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oxygen plus local anaesthetic (LA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: N(2)O/O(2) plus LA and Oxygen plus LA
Number of subjects: 48